Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En ny vaksine (EO2463) som monoterapi og i kombinasjon, for behandling av pasienter med indolent non-Hodgkin lymfom (SIDNEY)

2. november 2026 oppdatert av: Enterome

En global multisenter fase 1/2-studie av EO2463, en ny mikrobiell-avledet peptidterapeutisk vaksine, som monoterapi, og i kombinasjon med lenalidomid og rituximab, for behandling av pasienter med indolent non-Hodgkins lymfom

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

Studieoversikt

Detaljert beskrivelse

EO2463 Is an innovative cancer peptide therapeutic vaccine based on the homologies between tumor associated antigens and microbiome-derived peptides that will be administered alone and in combination with lenalidomide, rituximab, and lenalidomide/rituximab to generate safety and preliminary efficacy data in patients with indolent NHL

Studietype

Intervensjonell

Registrering (Antatt)

80

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Dana Farber Cancer Institute
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Mayo Clinic
    • New York
      • Rochester, New York, Forente stater, 14642
        • University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
    • Washington
      • Seattle, Washington, Forente stater, 98109
        • University of Washington-Seattle Cancer Care Alliance
      • Amiens, Frankrike
        • CHU d'Amiens-Picardie - Hopital SUD
      • Naples, Italia
        • IRCCS Policlinico San Matteo Foundation - University of Pavia
      • Pavia, Italia
        • IRCCS Policlinico San Matteo Foundation - University of Pavia
      • Barcelona, Spania
        • University Hospital Vall d'Hebron, Institute of Oncology
      • Madrid, Spania
        • Clinica Universidad de Navarra
      • Pamplona, Spania
        • Clinica Universidad de Navarra
      • Salamanca, Spania
        • Hospital Clinico Universitario de Salamanca

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. For inclusion in Cohorts 1 and 4 patients should have relapsed/refractory, biopsy-proven grade 1, 2 or 3A, FL or MZL, ECOG performance status 0 to 2, and have received at least one prior line of treatment. For inclusion in Cohort 4b the above applies except that patients with FL, and not patients with MZL, will be eligible for enrollment.
  2. For inclusion in Cohort 2 patients should have newly diagnosed, previously untreated (radiotherapy as only prior treatment is allowed), biopsy-proven grade 1, 2 or 3A, FL or MZL. ECOG performance status 0 or 1, low tumor burden by Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, and not be in need of standard of care therapy according to the assessment of the treating physician.
  3. For inclusion in Cohort 3 patients should have newly diagnosed, previously untreated (radiotherapy as only prior treatment is allowed), biopsy-proven grade 1, 2 or 3A, FL or MZL. ECOG performance status 0 or 1, low tumor burden by GELF criteria and be in need of therapy according to the assessment of the treating physician.
  4. Patients with an age ≥ 18 years old.
  5. Patients who are human leukocyte antigen (HLA)-A2 positive.
  6. Patients should have radiologically measurable disease with a lymph node or tumor mass greater than or equal to 1.5 cm in at least one dimension.
  7. Males or non-pregnant, non-lactating, females.
  8. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.
  9. Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures.

Exclusion Criteria:

  1. Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2463 administration, unless required to treat an adverse event.
  2. Patients with grade 3B FL or transformation to an aggressive lymphoma subtype.
  3. Patients with only one prior treatment and a high-risk profile as defined by first progression of disease within 24 months of diagnosis (the exclusion is not applicable for patients with more than one prior line treatment).
  4. Patients with prior exposure to EO2463.
  5. Patients treated with immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications), radionuclide therapy, radiotherapy, cytoreductive therapy, or received treatment with any other investigational agent within 28 days before the first EO2463 administration.
  6. Patients to be included in Cohorts 1 and 4, and who have received rituximab or other B cell ablation therapy within 8 weeks of start of study treatment.
  7. Patients to be included in Cohorts 4, who received prior CAR T-cell therapy and progressed within 6 months after this therapy.
  8. Patients with abnormal laboratory values.
  9. Patients with persistent Grade 3 or 4 toxicities.
  10. Uncontrolled central nervous system (CNS) metastasis.
  11. Other malignancy or prior malignancy with a disease-free interval of less than 3 years.
  12. Patients with clinically significant disease.
  13. Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g. Guillain-Barré syndrome).
  14. Patients with history of solid organ transplantation or allogeneic hematopoietic stem cell transplantation.
  15. Pregnant and breastfeeding patients.
  16. Patients with history or presence of human immunodeficiency virus and/or potentially active hepatitis B virus/hepatitis C virus infection.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cohort 1

Safety Lead-In, Dose-Finding, Cohort, with a 3-by-3 design of EO2463 monotherapy for 6 weeks followed by addition of lenalidomide. Then, if applicable rituximab (depending on response with EO2463 + lenalidomide) will be added. Four to 18 previously treated patients with Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) were anticipated to be included based on safety findings.

Multiple dose of EO2463

D1-21 of 4-weekly cycles

Andre navn:
  • Revlimid

Multiple doses of rituximab

Andre navn:
  • MabThera
Eksperimentell: Cohort 2

Anticipated approximatively 25 previously untreated patients with FL or MZL with an evaluation of EO2463 monotherapy (at the established dose in Cohort 1).

Multiple dose of EO2463

Eksperimentell: Cohort 3

Anticipated approximatively 6 previously untreated patients with FL or MZL with an evaluation of EO2463 (at the established dose in cohort 1) as monotherapy for 6 weeks followed by addition of rituximab if applicable (depending on response with EO2463 monotherapy).

Multiple dose of EO2463

Multiple doses of rituximab

Andre navn:
  • MabThera
Eksperimentell: Cohort 4

Anticipated approximatively 40 patients previously treated patients with FL (or MZL). Evaluation of EO2463 (at the established dose in Cohort 1) in combination with lenalidomide from day 1 and then with addition of rituximab.

Multiple dose of EO2463

D1-21 of 4-weekly cycles

Andre navn:
  • Revlimid

Multiple doses of rituximab

Andre navn:
  • MabThera

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |
Tidsramme: Up to 24 months

Incidences of adverse events, Treatment-Emergent Adverse events, Serious Adverse Events, Deaths, and Laboratory Abnormalities Using the National Cancer Institute-Common Terminology Criteria for Adverse events (NCI-CTCAE) V5.0.

Up to 24 months
Phase 2: Overall Response Rate
Tidsramme: Up to 24 months

Overall Response Rate According to the Lugano Classification 2014 during EO2463 Monotherapy

Up to 24 months
Phase 2: Complete Response Rate
Tidsramme: Up to 24 months

Complete remission (CR)-rate according to the Lugano Classification 2014 during therapy with the combination of EO2463/lenalidomide/rituximab.

Up to 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assessment of the Immunogenicity in Relation to OMP72, OMP64, OMP65, OMP66, and UCP2 that Compose EO2463
Tidsramme: Up to 24 months

Immunogenicity will be assessed by interferon-Gamma (IFN-Γ) enzyme-Linked immunospot , and/or by intracellular cytokines staining, and/or multimers staining assays.

Up to 24 months
Evaluation of Overall Survival
Tidsramme: Up to 7 years after last patient enrolled

The time interval from the date of first study treatment administration to the date of death due to any cause

Up to 7 years after last patient enrolled

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Jan Fagerberg, MD, Enterome

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. juli 2021

Primær fullføring (Antatt)

30. mai 2029

Studiet fullført (Antatt)

30. mai 2034

Datoer for studieregistrering

Først innsendt

8. desember 2020

Først innsendt som oppfylte QC-kriteriene

14. desember 2020

Først lagt ut (Faktiske)

16. desember 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere